You just read:

New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease

News provided by

Ionis Pharmaceuticals, Inc.

Apr 24, 2018, 12:15 ET